Annette, a Paris-based medical support platform dedicated to chronic obesity care and patients using GLP-1 treatments, has raised €2 million to provide a follow-up delivered by a clinical team and coordinated through a clinical companion app.
The round was led by Redstone, Ring Capital and AFI Ventures (Ventech – early stage fund) Clover VC, and Gfund.
“We use both clinical and subjective data (satiety, energy, symptoms…) to synchronise the care team around each patient, detect early signals, and adjust at the right moment. Technology acts as a safety net: it augments the human touch – it never replaces it,” says Gwen Le Calvez, co-founder and Chief Product and Technology Officer, Annette.
Annette’s €2 million raise comes amid a steady flow of 2025 European funding into digital chronic-care and obesity-related HealthTech.
In Poland, Holi secured €3 million to expand its data-driven digital obesity clinic across Europe, while Doctor.One raised €4 million to scale its asynchronous chronic-care model, which includes support for metabolic and obesity-related conditions. In France – Annette’s home market – RDS raised €14 million to industrialise its remote-monitoring patch, signalling ongoing investor confidence in French HealthTech infrastructure more broadly.
Together, these 2025 rounds amount to roughly €21 million of capital flows in adjacent chronic-care and monitoring solutions, rising to ~€23 million when including Annette.
Within this context, Annette stands out as one of the few French companies specifically targeting GLP-1–supported obesity care, and its raise aligns with the wider 2025 trend towards integrated, multidisciplinary chronic-care platforms across Europe.
“These results are not driven by the treatment alone: they occur when medication is paired with structure, nutritional guidance, emotional support, and a gradual adaptation to the body’s rhythm. This is precisely what Annette delivers – turning a treatment into a true long-term care pathway,” adds François-Xavier Trancart, co-founder and CEO, Annette.
Founded in 2024 by two repeat entrepreneurs – François-Xavier Trancart (Artsper) and Gwen Le Calvez (Birdie) – Annette structures long-term GLP-1 and chronic obesity care through a multidisciplinary team coordinated via a companion-app, ensuring treatment safety and helping patients achieve lasting results.
Annette provides a companion-app designed as a natural extension of medical care for patients starting GLP-1 treatments. The platform organizes GLP-1 follow-up around a multidisciplinary clinical team:
- A private messaging channel with Annette experts (dietitians, physical activity coaches, psychologists, etc.)
- Guided pathways tailored to each phase of the treatment
- Monitoring of key bodily signals: hunger, satiety, energy, digestion, treatment adherence
- Guidance toward a physician for evaluation, dose adjustments, or stabilisation
- A supportive community, so patients never progress alone
Today, more than 1,000 patients are supported through Annette, which reportedly boasts an average weight loss above clinical trial outcomes, a 90% retention rate at three months, and an NPS of +70.
Annette’s currentcare model is based on a €49 monthly subscription.
“At AFI Ventures, we back entrepreneurs who use technology to tackle society’s most pressing challenges. Obesity is clearly one of them. What makes us particularly enthusiastic about Annette is the rare combination of an ambitious vision, scientific rigor, and a product capable of creating meaningful impact for millions of people. We are convinced that the Annette team is building a solution that can truly move the needle,” says Constantin de Chaudenay, Investor at AFI Ventures
Obesity is a chronic and multifactorial disease, influenced by biology, emotions, and environment. It is now recognided as a major public health issue in France and across Europe. According to the 2024 national OFÉO study:
- 48.8% of adults in France are overweight or living with obesity
- including 18% with obesity – that is nearly 10 million people
Annette explains that if care pathways do not improve, the prevalence of obesity could reach 30% of the population by 2030.
The arrival of GLP-1 treatments (Wegovy, Mounjaro) marks a major milestone, but the company outlines that international experience has shown the risks when these medications are used without proper supervision: isolated prescriptions, lack of follow-up, and significant weight regain.
Without nutritional structure, emotional support, tailored physical activity, and ongoing medical follow-up, the benefits fade and the risk of regain increases. This is precisely where Annette looks to come in.
“The treatment can reduce appetite. But it does not rewrite eating habits or the relationship with one’s body. Medical and behavioral support makes it possible to transform how one eats, moves, and feels. It is the combination of both that truly shifts the weight trajectory – and makes it last,” explains Dr Lysiane Jubin, Chief Medical Officer, Annette.
This new funding round will enable Annette to scale its model to tens of thousands of patients, in France and then across Europe, focusing on three priorities:
- Accelerating the clinical companion-app (personalisation, follow-up, stabilization).
- Expanding and coordinating the multidisciplinary medical network, in close collaboration with primary care physicians.
- Strengthening prevention and education around obesity and the responsible use of GLP-1 treatments.
Read the orginal article: https://www.eu-startups.com/2025/12/addressing-europes-obesity-burden-french-medtech-startup-annette-closes-e2-million-round-for-structured-glp-1-support/
